Veracyte Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Veracyte stock.
View analyst ratings for Veracyte or view top-rated stocks.

7 brokers have issued 1 year target prices for Veracyte's stock. Their VCYT stock forecasts range from $26.00 to $59.00. On average, they expect Veracyte's share price to reach $42.14 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price.
View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT shares have decreased by 51.5% and is now trading at $19.97.
View the best growth stocks for 2022 here.

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The biotechnology company earned $67.78 million during the quarter, compared to analyst estimates of $61.98 million. Veracyte had a negative trailing twelve-month return on equity of 4.09% and a negative net margin of 19.22%. During the same quarter in the previous year, the business posted ($0.11) earnings per share.
View Veracyte's earnings history.

Veracyte issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.00 million-$275.00 million, compared to the consensus revenue estimate of $270.30 million.

Some companies that are related to Veracyte include Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Invitae (NVTA), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), DermTech (DMTK), Personalis (PSNL), Renalytix (RNLX), Genetron (GTH) and Progenity (PROG).
View all of VCYT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $19.97.

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.43 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75.56 million in net income (profit) each year or ($0.680010) on an earnings per share basis.

Veracyte employs 761 workers across the globe.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Veracyte is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at [email protected], or via fax at 650-243-6301.